Sarepta provides update on uk dosing in envision study of elevidys for the treatment of duchenne muscular dystrophy

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, shared the following update related to elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with duchenne muscular dystrophy. we have received feedback from the medicines & healthcare products regulatory agency (mhra) in the united kingdom (u.k.) that dosing may continue uninterrupted in envision, study srp-9001-303. en.
SRPT Ratings Summary
SRPT Quant Ranking